Why Xoma, a drug royalty firm, is hunting biotech ‘zombies' [Yahoo! Finance]
LAVA Therapeutics N.V. - Ordinary Shares (LVTX)
Company Research
Source: Yahoo! Finance
Four years ago, a record number of biotechnology companies flooded public markets , capitalizing on investor interest in drugmakers amid the COVID-19 pandemic. Since then, though, many of those once high-flying biotechs have failed to meet expectations, leaving scores of them worth less than the cash in their bank accounts. Historically, struggling biotechs would attempt to pivot, staking their future on a different strategy, a sale, or even a merger with a privately held firm. But recently, frustrated investors are pressing these “zombie” biotechs to shut down and return cash to shareholders instead. This pressure has created an investment opportunity for an unlikely beneficiary. Over the last year or so, Xoma Royalty, a company known for betting on others' future drug revenues, has started winding down distressed biotechs. Through those deals, Xoma returns cash to shareholders waiting for a payout, and profits by selling the rest of a shuttering biotech's intellectual propert
Show less
Read more
Impact Snapshot
Event Time:
LVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LVTX alerts
High impacting LAVA Therapeutics N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
LVTX
News
- LAVA intents to delist from Nasdaq [Seeking Alpha]Seeking Alpha
- LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from NasdaqGlobeNewswire
- XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements [Yahoo! Finance]Yahoo! Finance
- XOMA GAAP EPS of $0.70 beats by $0.74, revenue of $9.35M misses by $2.12M [Seeking Alpha]Seeking Alpha
- LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline [Yahoo! Finance]Yahoo! Finance
LVTX
Earnings
- 3/28/25 - Beat
LVTX
Sec Filings
- 11/21/25 - Form 25-NSE/A
- 11/21/25 - Form S-8
- 11/21/25 - Form S-8
- LVTX's page on the SEC website